Powered by OpenAIRE graph
Found an issue? Give us feedback
image/svg+xml art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos Open Access logo, converted into svg, designed by PLoS. This version with transparent background. http://commons.wikimedia.org/wiki/File:Open_Access_logo_PLoS_white.svg art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos http://www.plos.org/ Dépôt Institutionel ...arrow_drop_down
image/svg+xml art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos Open Access logo, converted into svg, designed by PLoS. This version with transparent background. http://commons.wikimedia.org/wiki/File:Open_Access_logo_PLoS_white.svg art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos http://www.plos.org/
Dépôt Institutionel de l’Université catholique de Louvain et de l’Université Saint-Louis
Article . 2018
Data sources: Dépôt Institutionel de l’Université catholique de Louvain et de l’Université Saint-Louis
Claim

In 2018, the antihyperglycemic therapy of type 2 diabetes takes account of the cardiovascular risk: Review of the American Diabetes Association guidelines [Le traitement antihyperglycémiant du diabète de type 2 intègre en 2018 le risque cardiovasculaire: Le point sur les recommandations de l’associa

descriptionPublicationkeyboard_double_arrow_right Article 01 Jan 2018 Belgium French Publisher:Louvain Médical
Authors: Buysschaert, Martin;

handle: 2078.1/263931

In 2018, the antihyperglycemic therapy of type 2 diabetes takes account of the cardiovascular risk: Review of the American Diabetes Association guidelines [Le traitement antihyperglycémiant du diabète de type 2 intègre en 2018 le risque cardiovasculaire: Le point sur les recommandations de l’associa

Abstract

De nouvelles recommandations pour le traitement du diabète de type 2 ont été publiées par l’Association Américaine du Diabète. Le but de cet article est de les analyser, à la lumière des études récentes, y compris dans le champ cardiovasculaire.

Country
Belgium
Related Organizations
Keywords

agonistes GLP-1, macroangiopathie, gliflozines, Diabète de type 2, traitement

  • BIP!
    Impact byBIP!
    selected citations
    These citations are derived from selected sources.
    This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
    		 0
    popularity
    This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.
    		 Average
    influence
    This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
    		 Average
    impulse
    This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.
    		 Average
Powered by OpenAIRE graph
Found an issue? Give us feedback
selected citations
These citations are derived from selected sources.
This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
BIP!Citations provided by BIP!
popularity
This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.
BIP!Popularity provided by BIP!
influence
This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
BIP!Influence provided by BIP!
impulse
This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.
BIP!Impulse provided by BIP!
0
Average
Average
Average
Green